Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.017 AUD | +6.25% | -5.56% | -51.43% |
May. 22 | Chimeric Therapeutics' First-in-Human CHM CDH17 Study Opens for Enrollment; Shares Up 4% | MT |
May. 20 | Chimeric Therapeutics Receives Ethics Approval for CHM CDH17 Phase 1/2 Clinical Trial | MT |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 14.67M 9.67M |
---|---|---|---|---|---|
Net income 2024 * | -13M -8.57M | Net income 2025 * | -21M -13.84M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.79% |
1 day | +6.25% | ||
1 week | -5.56% | ||
Current month | -5.56% | ||
1 month | -34.62% | ||
3 months | -43.33% | ||
6 months | -39.29% | ||
Current year | -51.43% |
Managers | Title | Age | Since |
---|---|---|---|
Phillip Hains
DFI | Director of Finance/CFO | 64 | 23-07-11 |
Chief Tech/Sci/R&D Officer | - | 22-07-04 | |
Li Ren
CTO | Chief Tech/Sci/R&D Officer | - | 21-06-24 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lesley Russell
BRD | Director/Board Member | 63 | 20-08-27 |
Paul Hopper
FOU | Founder | 68 | 20-02-01 |
Phillip Hains
DFI | Director of Finance/CFO | 64 | 23-07-11 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 0.017 | +6.25% | 1,459,086 |
24-06-06 | 0.016 | -5.88% | 4,006,591 |
24-06-05 | 0.017 | -10.53% | 3,628,735 |
24-06-04 | 0.019 | 0.00% | 3,721,870 |
24-06-03 | 0.019 | +5.56% | 1,556,358 |
Delayed Quote Australian S.E., June 07, 2024 at 02:11 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.43% | 9.66M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- CHM Stock